US EditionImmunotherapy IMNN-001 extends survival in ovarian cancer: Data
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Immunotherapy IMNN-001 extends survival in ovarian cancer: Data
When added to standard care, Imunon’s immunotherapy candidate IMNN-001 extended the average survival for people with newly diagnosed advanced ovarian cancer by more than a year, according to new clinical trial data. These results will be shared in an oral presentation next week at the annual meeting of the American Society of Clinical Oncology, and will also be simultaneously published in the journal Gynecologic Oncology, per an Imunon press rel…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
